Clinical Trial Update: Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease [Phase 3]

View source ↗

Summary

Pfizer's open-label Phase 3 trial of sumanirole for Parkinson disease was terminated. The update covers safety, tolerability, and therapeutic response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Sumanirole (sumanirole)

Snippet

Sponsor: Pfizer | Conditions: Parkinson Disease | Phase 3 | Status: TERMINATED